NovelStem International Corp. (NSTM)
USD 0.01
(23.46%)
USD 0.01
(23.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.52 Million USD | 1148.31% |
| 2022 | 282.1 Thousand USD | 208.87% |
| 2021 | 91.33 Thousand USD | 201.94% |
| 2020 | -89.59 Thousand USD | 0.0% |
| 2013 | -22.9 Million USD | -101.61% |
| 2012 | -11.36 Million USD | -208.74% |
| 2011 | -3.67 Million USD | 87.44% |
| 2010 | -29.3 Million USD | -154.25% |
| 2009 | -11.52 Million USD | 5.52% |
| 2008 | -12.19 Million USD | 53.46% |
| 2007 | -26.21 Million USD | -25.02% |
| 2006 | -20.96 Million USD | -3705.67% |
| 2005 | -550.92 Thousand USD | 89.6% |
| 2004 | -5.29 Million USD | -267.3% |
| 2003 | 3.16 Million USD | 309.17% |
| 2002 | -1.51 Million USD | -2304.23% |
| 2001 | -62.95 Thousand USD | -133.51% |
| 2000 | 187.89 Thousand USD | -81.21% |
| 1999 | 1 Million USD | -61.54% |
| 1998 | 2.6 Million USD | -3.7% |
| 1997 | 2.7 Million USD | 640.0% |
| 1996 | -500 Thousand USD | -150.0% |
| 1995 | -200 Thousand USD | 66.67% |
| 1994 | -600 Thousand USD | 94.0% |
| 1993 | -10 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 4.1 Million USD | 5.02% |
| 2024 Q1 | 3.9 Million USD | 10.92% |
| 2023 Q1 | 316.96 Thousand USD | 12.36% |
| 2023 FY | 3.52 Million USD | 1148.31% |
| 2023 Q4 | 3.52 Million USD | 8.15% |
| 2023 Q3 | 3.25 Million USD | 21.09% |
| 2023 Q2 | 2.68 Million USD | 748.4% |
| 2022 Q3 | 151.31 Thousand USD | 625.57% |
| 2022 Q4 | 282.1 Thousand USD | 86.43% |
| 2022 FY | 282.1 Thousand USD | 208.87% |
| 2022 Q1 | -102.77 Thousand USD | -212.52% |
| 2022 Q2 | 20.85 Thousand USD | 120.29% |
| 2021 Q1 | 89.59 Thousand USD | 0.0% |
| 2021 FY | 91.33 Thousand USD | 201.94% |
| 2021 Q4 | 91.33 Thousand USD | 0.0% |
| 2020 FY | -89.59 Thousand USD | 0.0% |
| 2013 Q3 | -24.82 Million USD | -157.98% |
| 2013 FY | -22.9 Million USD | -101.61% |
| 2013 Q1 | -9.89 Million USD | 12.89% |
| 2013 Q2 | -9.62 Million USD | 2.75% |
| 2013 Q4 | -22.9 Million USD | 7.75% |
| 2012 Q2 | -2.37 Million USD | 28.45% |
| 2012 Q3 | -5.93 Million USD | -149.45% |
| 2012 Q4 | -11.36 Million USD | -91.37% |
| 2012 FY | -11.36 Million USD | -208.74% |
| 2012 Q1 | -3.32 Million USD | 9.62% |
| 2011 Q3 | -5.49 Million USD | -22.08% |
| 2011 FY | -3.67 Million USD | 87.44% |
| 2011 Q1 | -5.5 Million USD | 81.2% |
| 2011 Q4 | -3.67 Million USD | 33.03% |
| 2011 Q2 | -4.5 Million USD | 18.29% |
| 2010 Q2 | -6.67 Million USD | 32.08% |
| 2010 Q4 | -29.3 Million USD | -306.6% |
| 2010 Q3 | -7.2 Million USD | -8.01% |
| 2010 Q1 | -9.82 Million USD | 14.76% |
| 2010 FY | -29.3 Million USD | -154.25% |
| 2009 Q4 | -11.52 Million USD | -21.68% |
| 2009 Q1 | -10.37 Million USD | 14.92% |
| 2009 FY | -11.52 Million USD | 5.52% |
| 2009 Q2 | -8.05 Million USD | 22.4% |
| 2009 Q3 | -9.47 Million USD | -17.61% |
| 2008 Q1 | -22.86 Million USD | 12.79% |
| 2008 FY | -12.19 Million USD | 53.46% |
| 2008 Q3 | -13.84 Million USD | 32.2% |
| 2008 Q2 | -20.42 Million USD | 10.67% |
| 2008 Q4 | -12.19 Million USD | 11.9% |
| 2007 Q1 | -13.81 Million USD | 34.11% |
| 2007 FY | -26.21 Million USD | -25.02% |
| 2007 Q4 | -26.21 Million USD | 22.99% |
| 2007 Q3 | -34.04 Million USD | -173.44% |
| 2007 Q2 | -12.44 Million USD | 9.88% |
| 2006 Q2 | 2.93 Million USD | 71.76% |
| 2006 Q4 | -20.96 Million USD | 1.15% |
| 2006 FY | -20.96 Million USD | -3705.67% |
| 2006 Q3 | -21.2 Million USD | -822.26% |
| 2006 Q1 | 1.7 Million USD | 410.32% |
| 2005 Q4 | -550.92 Thousand USD | 70.44% |
| 2005 Q3 | -1.86 Million USD | 11.42% |
| 2005 Q2 | -2.1 Million USD | 22.74% |
| 2005 Q1 | -2.72 Million USD | 48.58% |
| 2005 FY | -550.92 Thousand USD | 89.6% |
| 2004 Q4 | -5.29 Million USD | -112.98% |
| 2004 FY | -5.29 Million USD | -267.3% |
| 2004 Q1 | -8.24 Million USD | -360.56% |
| 2004 Q2 | -4.48 Million USD | 45.63% |
| 2004 Q3 | -2.48 Million USD | 44.55% |
| 2003 Q2 | 3.12 Million USD | 7.91% |
| 2003 Q1 | 2.89 Million USD | 291.24% |
| 2003 FY | 3.16 Million USD | 309.17% |
| 2003 Q3 | 4.37 Million USD | 39.96% |
| 2003 Q4 | 3.16 Million USD | -27.58% |
| 2002 FY | -1.51 Million USD | -2304.23% |
| 2002 Q3 | -1.46 Million USD | -310.46% |
| 2002 Q4 | -1.51 Million USD | -3.58% |
| 2002 Q2 | 694.31 Thousand USD | 645.52% |
| 2002 Q1 | -127.27 Thousand USD | -102.17% |
| 2001 Q1 | 552.01 Thousand USD | 193.79% |
| 2001 FY | -62.95 Thousand USD | -133.51% |
| 2001 Q2 | -3.16 Million USD | -673.29% |
| 2001 Q4 | -62.95 Thousand USD | 92.2% |
| 2001 Q3 | -806.84 Thousand USD | 74.5% |
| 2000 Q3 | -2.7 Million USD | -373.63% |
| 2000 Q4 | 187.89 Thousand USD | 106.95% |
| 2000 Q2 | 987.91 Thousand USD | 132.18% |
| 2000 Q1 | -3.06 Million USD | -406.99% |
| 2000 FY | 187.89 Thousand USD | -81.21% |
| 1999 Q4 | 1 Million USD | 143.48% |
| 1999 Q3 | -2.3 Million USD | -228.57% |
| 1999 FY | 1 Million USD | -61.54% |
| 1999 Q1 | 2.3 Million USD | -11.54% |
| 1999 Q2 | -700 Thousand USD | -130.43% |
| 1998 Q2 | 4.9 Million USD | 11.36% |
| 1998 Q3 | 4.2 Million USD | -14.29% |
| 1998 Q4 | 2.6 Million USD | -38.1% |
| 1998 Q1 | 4.4 Million USD | 62.96% |
| 1998 FY | 2.6 Million USD | -3.7% |
| 1997 Q3 | - USD | -100.0% |
| 1997 FY | 2.7 Million USD | 640.0% |
| 1997 Q4 | 2.7 Million USD | 0.0% |
| 1997 Q1 | 500 Thousand USD | 200.0% |
| 1997 Q2 | 600 Thousand USD | 20.0% |
| 1996 Q4 | -500 Thousand USD | -225.0% |
| 1996 FY | -500 Thousand USD | -150.0% |
| 1996 Q1 | 1.7 Million USD | 950.0% |
| 1996 Q2 | -1.6 Million USD | -194.12% |
| 1996 Q3 | 400 Thousand USD | 125.0% |
| 1995 FY | -200 Thousand USD | 66.67% |
| 1995 Q3 | -1.4 Million USD | 0.0% |
| 1995 Q4 | -200 Thousand USD | 85.71% |
| 1994 Q4 | -600 Thousand USD | 14.29% |
| 1994 FY | -600 Thousand USD | 94.0% |
| 1994 Q2 | -1 Million USD | 0.0% |
| 1994 Q3 | -700 Thousand USD | 30.0% |
| 1993 Q4 | -10 Million USD | 0.0% |
| 1993 FY | -10 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | -59.634% |
| Arrayit Corporation | 1.05 Million USD | -233.611% |
| Atlantic International Corp. | 236.49 Thousand USD | -1389.047% |
| Biocept, Inc. | -788 Thousand USD | 546.895% |
| Bioqual, Inc. | -12 Million USD | 129.329% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -15386.767% |
| DermTech, Inc. | 17.65 Million USD | 80.051% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 100.615% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 147.737% |
| iMD Companies, Inc. | 1.11 Million USD | -215.574% |
| IDenta Corp. | 524.85 Thousand USD | -570.958% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 54.23% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 13165.954% |
| InVitro International | -313.14 Thousand USD | 1224.581% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | -124.887% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 494004.067% |
| Medical Imaging Corp. | 3.79 Million USD | 7.106% |
| Optigenex Inc. | 8.93 Million USD | 60.583% |
| PharmChem, Inc. | -1.49 Million USD | 335.647% |
| Proteome Sciences plc | 14.57 Million USD | 75.836% |
| Response Genetics, Inc | -13.08 Million USD | 126.911% |
| Rennova Health, Inc. | 14.82 Million USD | 76.254% |
| RushNet, Inc. | 4.8 Million USD | 26.648% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -2497.214% |
| Stella Diagnostics Inc. | 6.19 Million USD | 43.137% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | -97.351% |
| Todos Medical Ltd. | 38.31 Million USD | 90.809% |